Scientists have developed a new therapy designed to repair cardiac damage after a heart attack. The study, led by researchers at Columbia University and published in the journal Nature Biomedical ...
In people with mild to moderate hypertension taken off antihypertensive treatment, quarterly and biannual injections of novel RNA silencer zilebesiran showed promise for safely reducing systolic blood ...
Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body ...
Morning Overview on MSN
RNA-based therapy reaches proof-of-concept for autism-related gene mutations in preclinical models
A single injection into the bloodstream of a mouse corrected a mutation linked to autism in neurons throughout the brain and ...
Zilebesiran, an interfering RNA, administered every 3-6 months lowers blood pressure in patients with mild to moderate hypertension. For patients with mild to moderate hypertension, a single injection ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A single self‑amplifying RNA injection that boosts a heart‑healing peptide cut scarring and ...
In this Peek Behind the Paper, we learn more about a recently published paper by Joaquin Abugattas-Nuñez Del Prado (Leiden University, The Netherlands; Universidad Peruana Cayetano Heredia, Lima, Perú ...
Misshapen proteins cause a mess of trouble—particularly in neurodegenerative diseases. But a new study suggests it's possible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results